- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.09. | AB&B BIO-TECH-B (02627): QUARTERLY UPDATE ON RESUMPTION PROGRESS AND CONTINUED SUSPENSION OF TRADING | - | HKEx | ||
| 23.09. | AB&B BIO-TECH-B (02627): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 23.09. | AB&B BIO-TECH-B (02627): (I) RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF FINANCIAL OFFICER (II) NOMINATION OF EXECUTIVE DIRECTORS (III) APPOINTMENT OF ... | 1 | HKEx | ||
| 31.08. | AB&B BIO-TECH-B (02627): INSIDE INFORMATION: (1) FURTHER DELAY IN PUBLICATION OF ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 AND ... | 1 | HKEx | ||
| 30.06. | AB&B BIO-TECH-B (02627): QUARTERLY UPDATE ON RESUMPTION PROGRESS; POSTPONEMENT OF THE 2025 ANNUAL GENERAL MEETING; AND CONTINUED SUSPENSION OF TRADING | - | HKEx | ||
| 23.06. | AB&B BIO-TECH-B (02627): VOLUNTARY ANNOUNCEMENT - IND APPROVAL BY CHINA CDE FOR MRNA MPOX VACCINE | 1 | HKEx | ||
| 05.06. | AB&B BIO-TECH-B (02627): APPOINTMENT OF INDEPENDENT INVESTIGATOR AND INDEPENDENT INTERNAL CONTROL CONSULTANT | 1 | HKEx | ||
| 27.05. | AB&B BIO-TECH-B (02627): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 2 | HKEx | ||
| AB&B BIO-TECH Aktie jetzt für 0€ handeln | |||||
| 27.05. | AB&B BIO-TECH-B (02627): ARTICLES OF ASSOCIATION | - | HKEx | ||
| 27.05. | AB&B BIO-TECH-B (02627): (1) POLL RESULTS OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026 (2) ABOLITION OF THE SUPERVISORY COMMITTEE, AMENDMENTS TO ... | - | HKEx | ||
| 13.05. | AB&B BIO-TECH-B (02627): VOLUNTARY ANNOUNCEMENT - COMMENCEMENT OF PHASE I AND PHASE II CLINICAL TRIALS FOR RECOMBINANT RSV VACCINE (CHO CELL) (ADJUVANT) | 1 | HKEx | ||
| 08.05. | AB&B BIO-TECH-B (02627): VOLUNTARY ANNOUNCEMENT - IND APPROVAL BY CHINA CDE FOR MRNA RSV VACCINE | 1 | HKEx | ||
| 08.05. | AB&B BIO-TECH-B (02627): FORM OF PROXY FOR THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026 TO BE HELD ON WEDNESDAY, MAY 27, 2026 AND ANY ADJOURNMENT THEREOF | 2 | HKEx | ||
| 08.05. | AB&B BIO-TECH-B (02627): (1) ABOLITION OF THE SUPERVISORY COMMITTEE (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION (3) AMENDMENTS TO CERTAIN INTERNAL CORPORATE ... | 1 | HKEx | ||
| 07.05. | AB&B BIO-TECH-B (02627): NOTICE OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026 | - | HKEx | ||
| 29.04. | AB&B BIO-TECH-B (02627): RESUMPTION GUIDANCE AND CONTINUED SUSPENSION OF TRADING | - | HKEx | ||
| 24.04. | AB&B BIO-TECH-B (02627): (I) NOMINATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR (II) CHANGE OF BOARD COMMITTEE MEMBERS AND (III) PROPOSED AMENDMENTS TO ... | - | HKEx | ||
| 24.04. | AB&B BIO-TECH-B (02627): PROPOSED APPOINTMENT OF AUDITOR | 3 | HKEx | ||
| 14.04. | AB&B BIO-TECH-B (02627): PROPOSED CHANGE OF AUDITOR | 1 | HKEx |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 259,86 | -1,40 % | Praxis Precision Medicine Q2 2026 Earnings Call Transcript | ||
| ERASCA | 16,030 | +3,69 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,590 | +2,45 % | Novo Nordisk zahlt bis zu 2,6 Milliarden Dollar für Biotech - warum Eli Lilly, GSK und AstraZeneca ebenfalls Milliarden auf neue Technologien setzen | ||
| QIAGEN | 40,190 | +1,55 % | Pharma-Aktien starten durch: Merck, Qiagen und Bayer im Höhenflug - KI-Boom und US-Megadeal befeuern Branche | Die Aktien von Pharma- und Biotech-Unternehmen erleben am Dienstag einen starken Aufwärtstrend, angeführt von Merck KGaA. Investoren setzen auf Übernahmespekulationen und den KI-getriebenen Innovationsschub... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,360 | 0,00 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| KINIKSA PHARMACEUTICALS | 79,78 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| MODERNA | 200,50 | +14,12 % | Moderna zeigt, wie schwierig der Sprung von der Studie zum Geschäftsmodell ist - ein Biotech aus Australien macht es vor | ||
| NURIX THERAPEUTICS | 22,350 | +0,63 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia | First patient enrolled in cohort combining bexobrutideg with venetoclax Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL Strategy includes evaluation... ► Artikel lesen | |
| ADMA BIOLOGICS | 10,360 | +0,29 % | Kehoe Law Firm, P.C.: ADMA Biologics (ADMA) Shareholder Alert: Kehoe Law Firm Investigates Potential Fiduciary Duty Breaches | Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - Kehoe Law Firm, P.C. is investigating whether certain officers and directors of ADMA Biologics, Inc. ("ADMA," "ADMA Biologics," or... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 112,45 | +2,88 % | Kymera Therapeutics: Raymond James startet Coverage mit "Outperform"-Rating | ||
| TANGO THERAPEUTICS | 23,820 | +5,59 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| IMMUNOVANT | 30,470 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| DYNE THERAPEUTICS | 16,645 | +1,68 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,020 | +3,12 % | $1000 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today | ||
| ABSCI | 10,165 | 0,00 % | Absci Corporation: Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis | Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial... ► Artikel lesen |
Das Unternehmen AB&B BIO-TECH CO LTD JS kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AB&B BIO-TECH CO LTD JS finden Sie auf Wallstreet Online.